Cargando…
A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis
OBJECTIVE: Variants in CLEC16A have conferred susceptibility to autoimmune diseases in genome-wide association studies. The present work aimed to investigate the locus' involvements in juvenile idiopathic arthritis (JIA) and further explore the association with rheumatoid arthritis (RA), type 1...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BMJ Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938883/ https://www.ncbi.nlm.nih.gov/pubmed/19734133 http://dx.doi.org/10.1136/ard.2009.114934 |
_version_ | 1782186683656044544 |
---|---|
author | Skinningsrud, Beate Lie, Benedicte A Husebye, Eystein S Kvien, Tore K Førre, Øystein Flatø, Berit Stormyr, Alice Joner, Geir Njølstad, Pål R Egeland, Thore Undlien, Dag E |
author_facet | Skinningsrud, Beate Lie, Benedicte A Husebye, Eystein S Kvien, Tore K Førre, Øystein Flatø, Berit Stormyr, Alice Joner, Geir Njølstad, Pål R Egeland, Thore Undlien, Dag E |
author_sort | Skinningsrud, Beate |
collection | PubMed |
description | OBJECTIVE: Variants in CLEC16A have conferred susceptibility to autoimmune diseases in genome-wide association studies. The present work aimed to investigate the locus' involvements in juvenile idiopathic arthritis (JIA) and further explore the association with rheumatoid arthritis (RA), type 1 diabetes (T1D) and Addison's disease (AD) in the Norwegian population. METHODS: Three single nucleotide polymorphisms (SNPs) were genotyped in patients with RA (n=809), JIA (n=509), T1D (n=1211) and AD (n=414) and in healthy controls (n=2149). RESULTS: All diseases were associated with CLEC16A, but with different SNPs. The intron 22 SNP, rs6498169, was associated with RA (p=0.006) and JIA (p=0.016) and the intron 19 SNPs, rs12708716/rs12917716, with T1D (p=1×10−5) and AD (p=2×10−4). The RA association was confined to the anti-cyclic citrullinated peptide antibody (anti-CCP) negative subgroup (p=2×10−4). CONCLUSION: This is the first report of a CLEC16A association with JIA and a split of the RA association according to anti-CCP status. Different causative variants underlie the rheumatic versus the organ specific diseases. |
format | Text |
id | pubmed-2938883 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BMJ Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-29388832010-09-15 A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis Skinningsrud, Beate Lie, Benedicte A Husebye, Eystein S Kvien, Tore K Førre, Øystein Flatø, Berit Stormyr, Alice Joner, Geir Njølstad, Pål R Egeland, Thore Undlien, Dag E Ann Rheum Dis Clinical and Epidemiological Research OBJECTIVE: Variants in CLEC16A have conferred susceptibility to autoimmune diseases in genome-wide association studies. The present work aimed to investigate the locus' involvements in juvenile idiopathic arthritis (JIA) and further explore the association with rheumatoid arthritis (RA), type 1 diabetes (T1D) and Addison's disease (AD) in the Norwegian population. METHODS: Three single nucleotide polymorphisms (SNPs) were genotyped in patients with RA (n=809), JIA (n=509), T1D (n=1211) and AD (n=414) and in healthy controls (n=2149). RESULTS: All diseases were associated with CLEC16A, but with different SNPs. The intron 22 SNP, rs6498169, was associated with RA (p=0.006) and JIA (p=0.016) and the intron 19 SNPs, rs12708716/rs12917716, with T1D (p=1×10−5) and AD (p=2×10−4). The RA association was confined to the anti-cyclic citrullinated peptide antibody (anti-CCP) negative subgroup (p=2×10−4). CONCLUSION: This is the first report of a CLEC16A association with JIA and a split of the RA association according to anti-CCP status. Different causative variants underlie the rheumatic versus the organ specific diseases. BMJ Group 2010-08-01 /pmc/articles/PMC2938883/ /pubmed/19734133 http://dx.doi.org/10.1136/ard.2009.114934 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. |
spellingShingle | Clinical and Epidemiological Research Skinningsrud, Beate Lie, Benedicte A Husebye, Eystein S Kvien, Tore K Førre, Øystein Flatø, Berit Stormyr, Alice Joner, Geir Njølstad, Pål R Egeland, Thore Undlien, Dag E A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis |
title | A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis |
title_full | A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis |
title_fullStr | A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis |
title_full_unstemmed | A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis |
title_short | A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis |
title_sort | clec16a variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis |
topic | Clinical and Epidemiological Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938883/ https://www.ncbi.nlm.nih.gov/pubmed/19734133 http://dx.doi.org/10.1136/ard.2009.114934 |
work_keys_str_mv | AT skinningsrudbeate aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT liebenedictea aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT husebyeeysteins aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT kvientorek aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT førreøystein aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT flatøberit aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT stormyralice aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT jonergeir aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT njølstadpalr aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT egelandthore aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT undliendage aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT skinningsrudbeate clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT liebenedictea clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT husebyeeysteins clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT kvientorek clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT førreøystein clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT flatøberit clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT stormyralice clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT jonergeir clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT njølstadpalr clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT egelandthore clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis AT undliendage clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis |